| Literature DB >> 28584963 |
Hiroshi Ohkawara1, Miki Furukawa2, Kazuhiko Ikeda2,3, Akiko Shichishima-Nakamura2, Masahiko Fukatsu2, Takahiro Sano2, Koki Ueda2, Satoshi Kimura2, Risa Kanai4, Yuka Oka4, Fumi Murakami4, Osamu Suzuki4, Yuko Hashimoto4, Kazuei Ogawa2, Takayuki Ikezoe2.
Abstract
We here report a 47-year-old female with autoimmune myelofibrosis (AIMF) associated with liver damage caused by autoimmune hepatitis and Evans syndrome. Bone marrow biopsy revealed hypocellular marrow with grade 2 reticulin fibrosis and increased levels of B lymphocytes (CD20+), T lymphocytes (CD3+, CD8+), and plasma cells (CD138+). Immunohistochemical analysis revealed increased expression of transforming growth factor-β (TGF-β) in infiltrating lymphocytes and macrophages in the bone marrow. She was initially treated with oral prednisolone (PSL) for 2 months, which had a limited effect. However, after treatment with rituximab, the patient's pancytopenia showed improvement, allowing us to rapidly reduce the PSL dosage. The present case suggests the possibility that increased expression of TGF-β in infiltrating lymphocytes and macrophages of bone marrow may contribute to the pathogenesis of AIMF. Prednisolone combined with rituximab may thus be an effective option for steroid-refractory cases.Entities:
Keywords: Autoimmune hepatitis; Autoimmune myelofibrosis; Evans syndrome; Rituximab; Transforming growth factor-β
Mesh:
Substances:
Year: 2017 PMID: 28584963 DOI: 10.1007/s12185-017-2268-3
Source DB: PubMed Journal: Int J Hematol ISSN: 0925-5710 Impact factor: 2.490